StandoutStocks.com: "Stocks that Standout" picks for today are: BCLE, BMRN, CLWR, NVAX, SWIR

May 15, 2009 (M2 PRESSWIRE via COMTEX) -- SWIR | Quote | Chart | News | PowerRating -- StandoutStocks.com "Stocks that Standout" picks for today are: Bio-Clean International, Inc. (PINKSHEETS: BCLE), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Clearwire Corporation (NASDAQ: CLWR), Novavax, Inc. (NASDAQ: NVAX), Sierra Wireless (NASDAQ: SWIR)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

May 15, 2009 -- Bio-Clean International, Inc. (PINKSHEETS: BCLE | Quote | Chart | News | PowerRating) announced today that its affiliated entity, American Bio-Clean Corporation, a Service-Disabled Veteran-Owned Small Business, has completed and fulfilled an order of EnviroTru Multi-Purpose Disinfectant & Deodorizing Cleaner to Miami Aerospace.

John Finn, COO of American Bio-Clean said, "Due to the recent Swine Flu scare around the World, there has been a bid demand for EnviroTru Multi-Purpose Disinfectant & Deodorizing Cleaner. As a result of our "Teaming Agreement" with Anpath Group, Inc., (OTCBB: ANPG) announced in February of this year, we have fulfilled an order for Miami Aerospace. Miami Aerospace has thirty-two years of combined experience in customer service, purchasing and sales relating to the aircraft industry and it is reported that in the past 21 years, it has become the largest distribution of Aviation Parts and Supplies." Mr. Finn went on to say, "EnviroTru's multi-purpose, disinfectant, sanitizer and deodorizing cleaner is effective against numerous organisms, including MRSA. It is registered by the Environmental Protection Agency (EPA) and meets requirements for Toxicity Category IV. In addition, use of it does not require protective clothing, gloves or special ventilation, and it has passed the AMS 1452A, AMS 1453 and Boeing D6-7127 specifications for non-corrosion and materials capability." About Bio-Clean International, Inc.

Bio-Clean International, Inc. recognizes the problems facing our environment. Our exclusive, non-toxic, bio-remediation fluids provide an environmentally-safe solution. Our exclusive products and machines have been tested and shown to be in complete compliance with environment regulations, in other words, "Cleantech".

Our majority-owned subsidiary, American Bio-Tech Cleaning, Inc. (ABT), designs and manufactures customized parts and weapons washing/cleaning systems that are eco-friendly, using a water-based cleaning fluid integrated with a self-contained bio-remediation process. We also own a minority interest in American Bio-Clean Corporation (ABC,) which markets and distributes our cleaning fluids and parts/weapons cleaning machines. ABC is a Service-Disabled Veteran-Owned Small Business (SDVOSB) that is certified and meets the Federal-mandated 3% minority spending requirements. Similar mandated spending requirements adopted by most states vary from 3% to 20%. Additionally, many private sector companies have targeted goals for suppliers.

We also maintain a minority interest in Veterans Training Corporation, (VTC), which is also a SDVOSB business based in Southern California and provides a wide range of training programs for a variety of clients including the U.S. Department of Defense. In addition, VTC provides training programs for the private sector such as its OSHA safety-training programs for the construction industry.

May 15, 2009 -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN | Quote | Chart | News | PowerRating) announced today that it has received the 2009 Corporate Award from the National Organization for Rare Disorders (NORD), an organization dedicated to improving the lives of people with rare diseases. The award was presented on May 14 at NORD's annual "Partners in Progress" Gala in Washington, D.C. It recognizes BioMarin's significant achievements toward improving the lives of people living with phenylketonuria (PKU).

NORD honored BioMarin for the development of Kuvan(R) (sapropterin dihydrochloride) Tablets, the first and only prescription medication for PKU. Kuvan is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). PKU is a rare genetic disorder that can cause brain damage and various neurological complications, including mental retardation, mental illness, seizures, tremors and cognitive problems. Designated as an orphan disease, PKU occurs in about one out of every 12,000 to 15,000 live births in the United States.

"It is a great honor to receive this award from NORD," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We are very pleased to be able to provide this important treatment option to PKU patients and we will continue to push our scientific research and product development efforts forward to meet the medical needs of PKU patients -- and those with other rare diseases."

Each year NORD selects organizations that have made a positive contribution to further the needs of the patient community and have inspired the public to do so as well. Since 2004, this is the third time BioMarin has been bestowed with this honor.

"Patients and families who live with PKU face a constant struggle to maintain their health balance, and BioMarin has been instrumental in giving PKU patients an opportunity to lower their Phe levels," said NORD president Peter Saltonstall. "We applaud BioMarin's efforts and look to more companies to make similar strides and provide treatment options to patients in rare disease communities."

In addition to attending the NORD Gala mid-month, BioMarin will participate in several PKU community events in support of PKU Awareness Month this May. Participation includes full sponsorship of a disease awareness campaign and a support program for patients who may require assistance with disease management. Locally, BioMarin employees will attend and sponsor community walks around the country and assist in fundraising efforts.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(C) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(C) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA.

May 14, 2009 -- Clearwire Corporation (NASDAQ: CLWR), a provider of high-speed wireless broadband services, and network technologies company Cisco (Nasdaq:CSCO) have announced an alliance designed to enhance and expand CLEAR 4G mobile WiMAX services throughout the US.

Under the terms of the agreement, Clearwire has selected Cisco as its national Internet Protocol Next-Generation Network (IP NGN) core infrastructure provider and Cisco has announced plans to build new mobile WiMAX devices for the CLEAR 4G mobile WiMAX service for the consumer, small office or home office (SOHO) and small and medium-sized business (SMB) markets.

According to the company, as part of a multiyear network build-out plan with Cisco, the CLEAR 4G mobile WiMAX service is to be available in major US metropolitan areas. The company's open all-IP network, combined with significant spectrum holdings, provides substantive network capacity to deliver next-generation broadband access. In addition, Cisco is aiming to introduce its first mobile WiMAX device later in 2009.

Clearwire has selected and is in the process of testing and certification of a Cisco IP NGN architecture that includes Cisco 7600 Series Internet routers, Cisco ONS 15454 and Cisco ONS 15310 platforms, Cisco ASA Firewalls and the Cisco Service and Application Module for IP (SAMI) Home Agent. The Cisco 7600 Series Routers are high-performance, intelligent routers designed for deployment at the network edge where performance, IP-enabled services, redundancy and fault resiliency are key requirements.

Future Cisco converged WiMAX and Wi-Fi enabled devices are to include products from Linksys by Cisco line of consumer routers. The company will also look to expand its WiMAX portfolio with the growth of the CLEAR 4G network across the US. The two companies will jointly develop and implement go-to-market plans that will benefit from Cisco's distribution channels and presence with consumers and businesses, which will assist to enhance and expand CLEAR mobile WiMAX services throughout the US, the company said.

The two companies also recently announced their involvement in forming the WiMAX Innovation Network for developers, which will initially cover over 20 square miles in Silicon Valley. Cisco will provide core Internet Protocol Next-Generation Network (IP NGN) core infrastructure equipment in support of the WiMAX Innovation Network. Service is expected to be available to developers by late summer 2009. Service will be provided free to a limited number of qualified developers for one year. Clearwire will provide WiMAX USB Modems for USD49.99.

May 15, 2009 -- Novavax, Inc. (NASDAQ: NVAX | Quote | Chart | News | PowerRating) announced today that enrollment has been completed in the second Phase II clinical trial of its trivalent virus-like particle (VLP) seasonal influenza vaccine. This Phase IIa randomized, placebo-controlled study is evaluating a VLP vaccine against the H3N2, H1N1, and B influenza strains that circulated in the 2008-2009 influenza season. This clinical trial represents another step in the development of Novavax's VLP seasonal influenza vaccine, allowing further evaluation of safety and immunogenicity of a broad range of vaccine doses against a new set of influenza strains. As announced in December of 2008, the first Phase II study evaluated a trivalent VLP vaccine against the seasonal influenza strains that circulated in the 2005-2006 influenza season.

Specifically, this new study is evaluating the safety and immunogenicity of the 2008-2009 influenza vaccine in approximately 220 healthy adults between the ages of 18 and 49 years. Subjects have received a single injection of either a placebo or the VLP vaccine at doses of 15 mcg or 60 mcg per strain. The results of this study will be used to help select a dose for further evaluation in a clinical trial involving adults 65 years of age and older later this year and in a subsequent Phase III efficacy study.

"Enrollment of this second Phase II clinical trial represents another important developmental milestone for our VLP seasonal influenza vaccine program," said Dr. Rahul Singhvi, President and CEO of Novavax. "This study provides the opportunity to evaluate the safety and immunogenicity of our VLP vaccine against a new set of influenza strains, further strengthening our growing clinical database for VLP-based influenza vaccines. The completion of enrollment keeps us on track for having top line data for the 2008-2009 vaccine in the third quarter of this year and for selecting a dose for a Phase II trial in older adults later this year."

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches.

May 15, 2009 -- Sierra Wireless (NASDAQ: SWIR - TSX: SW), a leading provider of wireless solutions for mobile computing and machine-to-machine (M2M) communication, announced changes to the Sierra Wireless executive leadership team as well as certain cost reduction initiatives related to the integration of Wavecom with Sierra Wireless.

Changes to the executive leadership team are as follows:

Didier Dutronc, previously Chief Sales Officer at Wavecom, has been appointed Senior Vice President, Marketing and will be responsible for all marketing and product management activities globally for the combined company.

Philippe Guillemette, formerly Group Vice President of Marketing and Chief Technology Officer at Wavecom, becomes Senior Vice President, Advanced Technology. Philippe will drive advanced technology initiatives and long range product/solution strategy for Sierra Wireless.

Pierre Teyssier, formerly Chief Operating Officer at Wavecom, becomes Senior Vice President, Engineering with overall responsibility for global engineering and product development activities for the combined company.

Emmanuel Walckenaer continues in his current role as CEO of Anyware Technologies and is appointed Senior Vice President & General Manager, Solutions and Services. His focus will be on rapidly growing the solutions and services business of the combined company.

Didier, Philippe, Pierre and Emmanuel join the existing members of the executive leadership team: Jason Cohenour - President and Chief Executive Officer; Bill Dodson - Senior Vice President, Operations; Dan Schieler - Senior Vice President, Worldwide Sales; David McLennan - Chief Financial Officer; Jim Kirkpatrick - Chief Technology Officer and Andrew Berman - Senior Vice President & General Manager, Mobile and M2M.

Commensurate with these appointments, Anders Franzen, CEO of Wavecom's US subsidiary and Steve Blaine, Senior Vice President, Engineering at Sierra Wireless will both be leaving the company in September. Additionally, Herbert Scheitler, Vice President, Automotive at Wavecom is leaving the company effective immediately. The responsibilities of Anders, Steve and Herbert will be absorbed by remaining members of the Sierra Wireless team.

"These appointments represent an important step in the integration of Wavecom with Sierra Wireless," said Jason Cohenour, President and CEO. "Going forward, the combined company will be led by an experienced and truly international executive team. I am confident that this team, combined with our expanded product lineup and unmatched global capabilities, will help us to drive leadership in wireless solutions for mobile computing and M2M.

I would also like to sincerely thank Steve, Anders and Herbert for the leadership, hard work and energy they have provided in building Sierra Wireless and Wavecom into two great companies. I wish them great success in their future endeavors."

Broader expense reduction initiatives are also underway. As part of the integration process, R&D and product development operations have been combined, and as a result, the Wavecom site in Research Triangle Park, NC will be closed. R&D activities from this location will be transitioned primarily to the Sierra Wireless location in Carlsbad, CA. The company expects a smooth transition and for the process to be completed by the end of the year.

As part of previously announced cost reduction initiatives, the staff reduction program in Wavecom's office in Issy-Les-Moulineaux near Paris, France has been completed. A total of 77 positions have been impacted. Of those employees affected, the majority will have left by the end of the second quarter, with the balance leaving throughout the second half of the year.

An update on the financial impact of these initiatives will be provided with Sierra Wireless' second quarter results in late July.

About Sierra Wireless

Sierra Wireless products connect people and machines to wireless networks around the world. We offer an advanced, comprehensive product line, addressing consumer, enterprise, original equipment manufacturer, and specialized vertical industry markets. We also offer a wide range of professional and operated services. Our solutions are used for mobile computing, transportation, industrial M2M (machine-to-machine), enterprise, residential and consumer communications applications.

About Standoutstocks.com

Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

CONTACT: Standoutstocks.com e-mail: info@standoutstocks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index